0|chunk|Key Role of Splenic Myeloid DCs in the IFN-ab Response to Adenoviruses In Vivo
0	4	8 Role	Chemical	CHEBI_50906
0	28	31 DCs	Chemical	CHEBI_40009
0	CHEBI-CHEBI	CHEBI_50906	CHEBI_40009

1|chunk|The early systemic production of interferon (IFN)-ab is an essential component of the antiviral host defense mechanisms, but is also thought to contribute to the toxic side effects accompanying gene therapy with adenoviral vectors. Here we investigated the IFN-ab response to human adenoviruses (Ads) in mice. By comparing the responses of normal, myeloid (m)DC-and plasmacytoid (p)DC-depleted mice and by measuring IFN-ab mRNA expression in different organs and cells types, we show that in vivo, Ads elicit strong and rapid IFN-ab production, almost exclusively in splenic mDCs. Using knockout mice, various strains of Ads (wild type, mutant and UV-inactivated) and MAP kinase inhibitors, we demonstrate that the Ad-induced IFN-ab response does not require Toll-like receptors (TLR), known cytosolic sensors of RNA (RIG-I/MDA-5) and DNA (DAI) recognition and interferon regulatory factor (IRF)-3, but is dependent on viral endosomal escape, signaling via the MAP kinase SAPK/JNK and IRF-7. Furthermore, we show that Ads induce IFN-ab and IL-6 in vivo by distinct pathways and confirm that IFN-ab positively regulates the IL-6 response. Finally, by measuring TNF-a responses to LPS in Ad-infected wild type and IFN-abR 2/2 mice, we show that IFN-ab is the key mediator of Ad-induced hypersensitivity to LPS. These findings indicate that, like endosomal TLR signaling in pDCs, TLR-independent virus recognition in splenic mDCs can also produce a robust early IFN-ab response, which is responsible for the bulk of IFN-ab production induced by adenovirus in vivo. The signaling requirements are different from known TLR-dependent or cytosolic IFN-ab induction mechanisms and suggest a novel cytosolic viral induction pathway. The hypersensitivity to components of the microbial flora and invading pathogens may in part explain the toxic side effects of adenoviral gene therapy and contribute to the pathogenesis of adenoviral disease.
1	33	43 interferon	Chemical	CHEBI_52999
1	86	95 antiviral	Chemical	CHEBI_22587
1	296	299 Ads	Chemical	CHEBI_73344
1	423	427 mRNA	Chemical	CHEBI_33699
1	498	501 Ads	Chemical	CHEBI_73344
1	621	624 Ads	Chemical	CHEBI_73344
1	668	671 MAP	Chemical	CHEBI_6716
1	668	689 MAP kinase inhibitors	Chemical	CHEBI_79091
1	813	816 RNA	Chemical	CHEBI_33697
1	835	838 DNA	Chemical	CHEBI_16991
1	861	871 interferon	Chemical	CHEBI_52999
1	961	964 MAP	Chemical	CHEBI_6716
1	1018	1021 Ads	Chemical	CHEBI_73344
1	1179	1182 LPS	Chemical	CHEBI_16412
1	1304	1307 LPS	Chemical	CHEBI_16412
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_73344
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_33699
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_6716
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_79091
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_33697
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_16991
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_16412
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_73344
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_33699
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_6716
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_79091
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_33697
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_16991
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_16412
1	CHEBI-CHEBI	CHEBI_73344	CHEBI_33699
1	CHEBI-CHEBI	CHEBI_73344	CHEBI_6716
1	CHEBI-CHEBI	CHEBI_73344	CHEBI_79091
1	CHEBI-CHEBI	CHEBI_73344	CHEBI_33697
1	CHEBI-CHEBI	CHEBI_73344	CHEBI_16991
1	CHEBI-CHEBI	CHEBI_73344	CHEBI_16412
1	CHEBI-CHEBI	CHEBI_33699	CHEBI_6716
1	CHEBI-CHEBI	CHEBI_33699	CHEBI_79091
1	CHEBI-CHEBI	CHEBI_33699	CHEBI_33697
1	CHEBI-CHEBI	CHEBI_33699	CHEBI_16991
1	CHEBI-CHEBI	CHEBI_33699	CHEBI_16412
1	CHEBI-CHEBI	CHEBI_6716	CHEBI_79091
1	CHEBI-CHEBI	CHEBI_6716	CHEBI_33697
1	CHEBI-CHEBI	CHEBI_6716	CHEBI_16991
1	CHEBI-CHEBI	CHEBI_6716	CHEBI_16412
1	CHEBI-CHEBI	CHEBI_79091	CHEBI_33697
1	CHEBI-CHEBI	CHEBI_79091	CHEBI_16991
1	CHEBI-CHEBI	CHEBI_79091	CHEBI_16412
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_16991
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_16412
1	CHEBI-CHEBI	CHEBI_16991	CHEBI_16412

